New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 12, 2014
15:25 EDTPVCT, PVCTProvectus Pharmaceuticals to host conference call
Conference Call to provide updates on the Phase 3 clinical trial of PV-10 will be held on June 19 at 4 pm. Webcast Link
News For PVCT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 6, 2015
08:12 EDTPVCTProvectus Phase 1 PV-10 data presented at APPLE 2015
Subscribe for More Information
July 2, 2015
06:34 EDTPVCTProvectus signs LOI with Boehringer Ingelheim China to sell PV-10 in China
Provectus has signed a Letter of Intent with Boehringer Ingelheim - China - Investment. The purpose of the LOI is to lay a foundation for the two parties to collaborate in bringing PV-10, Provectus’ novel investigational drug for cancer, to market in mainland China, Hong Kong and Taiwan. Under the terms of the LOI, Boehringer will provide certain commercially reasonable support in the aspects of product registration with the China FDA, communication preparation, market intelligence and other assistance to Provectus in China. In return, Provectus will grant Boehringer the first priority to be the exclusive collaborator of Provectus in China for PV-10 in the event that PV-10 is successfully registered and approved by the CFDA. At the appropriate time, Provectus and Boehringer will enter into a definitive agreement.
06:07 EDTPVCTProvectus' liver cancer candidate shows positive preliminary results
Provectus announced data from its phase 1 study of PV-10 for chemoablation of hepatocellular carcinoma and cancer metastatic to the liver presented at the ESMO 17th World Congress on Gastrointestinal Cancer. The main conclusion was that preliminary evidence of efficacy in treatment of liver cancers with PV-10 was observed. The current phase 1 study was designed to assess safety, pharmacokinetics, and preliminary efficacy of PV-10 in subjects with non-resectable HCC or other types of cancer metastatic to the liver. The study is continuing at three study centers with two expansion cohorts to further assess safety and response in HCC and other cancers metastatic to the liver.
June 26, 2015
08:33 EDTPVCTProvectus says PV-10 data shows treatment ‘possesses favorable safety’
Provectus Biopharmaceuticals announced that Dr. Vernon Sondak presented data on “Intralesional Therapy for Melanoma with PV-10” during the 5th European Post-Chicago Melanoma/Skin Cancer Meeting in Munich, Germany. Dr. Sondak spoke during “Symposium III – New Drugs and Trials I: Immunotherapy,” held June 25. His conclusions included that “among the many agents currently being evaluated for use as intralesional therapy for melanoma, PV-10 possesses favorable safety and handling properties and induces rapid ablation of injected lesions to a degree similar to or possibly better than other agents,” and “preclinical and clinical data suggest PV-10 would be a good candidate to evaluate in conjunction with available systemic immunotherapies.”

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use